Kevin Church - 28 Oct 2022 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Executive VP, Research
Signature
Glenna Mileson, Attorney-in-fact for Kevin Church
Issuer symbol
ATHA
Transactions as of
28 Oct 2022
Net transactions value
+$4,995
Form type
4
Filing time
31 Oct 2022, 20:17:37 UTC
Previous filing
24 Jun 2022
Next filing
23 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATHA Common Stock Options Exercise $4,995 +3,700 +6.4% $1.35 61,395 28 Oct 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Options Exercise $0 -3,700 -37% $0.000000 6,410 28 Oct 2022 Common Stock 3,700 $1.35 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares subject to the option vested on January 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.